Blog

Gigi DeGuzman

August 21, 2025
Posted by scilexpharma

Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operations management, facilities management, event planning, executive coordination, and administrative operations. She has played a significant role...

Dmitri Lissin, MD

August 21, 2025
Posted by Jitendra

Dmitri Lissin currently serves as Interim Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Scilex/Semnur Pharmaceuticals (2015 – present). Prior to Semnur, from 2011-2015, Dmitri was Vice President...

Gloperba Launch – Nasdaq-2024

June 18, 2025
Posted by scilexpharma

Gloperba Launch – Nasdaq-2024

14 Jun

Publications

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

June 14, 2024
Posted by Jitendra

20 May

Publications

Gout Awareness Day – May 22

May 20, 2024
Posted by Jitendra

14 Mar

Publications

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

March 14, 2024
Posted by Ulisses

14 Mar

Publications

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch

March 14, 2024
Posted by Ulisses

05 Mar

Press Release

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

March 5, 2024
Posted by scilexpharma

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

05 Mar

Press Release

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

March 5, 2024
Posted by scilexpharma

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated...

04 Mar

Press Release

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

March 4, 2024
Posted by scilexpharma

Redesigned website reflects the Company's expanded pipeline of non-opioid pain management products and links to its recent publications and news PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an...

Gigi DeGuzman

Dmitri Lissin, MD

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

Henry Ji, PhD

Stephen Ma

Jaisim Shah

Dorman Followwill

Alexander Wu, PhD